VOYAGER DIGITAL LT
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 162
- Market Cap
- $361.5M
- Introduction
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Lexington, MA.
Vima Therapeutics Emerges with $60M to Develop First Oral Therapy for Dystonia
Vima Therapeutics launched with $60 million Series A funding led by Atlas Venture to advance VIM0423, a potential first-in-class oral therapy for dystonia targeting muscarinic cholinergic receptors.
Voyager Therapeutics Redirects SOD1 ALS Gene Therapy Development After Preclinical Findings
Voyager Therapeutics announces strategic shift in their SOD1 ALS gene therapy program after three-month non-human primate data indicated the need for alternate payload evaluation.
Bayer's Cell and Gene Therapy Programs for Parkinson's Disease Enter Clinical Trials
Bayer's BlueRock Therapeutics initiated a Phase 1 trial of DA01, a cell-based therapy using stem cell-derived dopaminergic neurons, to replenish lost neurons in Parkinson's patients.
Gene and Cell Therapies Show Promise in Treating CNS Disorders
The market for gene and cell therapies targeting CNS disorders was valued at approximately USD 1 billion in 2021 and is projected to grow significantly by 2034.
OrsoBio Secures $67M for Obesity Drugs, Vor Bio's AML Therapy Shows Promise, and More
OrsoBio, backed by Eli Lilly, raised $67 million to advance its portfolio of weight loss medicines targeting different mechanisms than GLP-1 therapies.